-
1.发明申请公开(公告)号：US20210309656A1
公开(公告)日：2021-10-07
申请号：US17265266
申请日：2019-08-06
发明人： Rajiv Sharma , Lambertus Benthem , Robert Judkins
IPC分类号： C07D451/06 , C07D413/12 , C07D261/08
摘要： Provided are compounds that can act as a modulator of a farnesoid X receptor (FXR) and that can be useful in the treatment of diseases and/or disorders associated with the FXR. Compositions including such compounds are also provided along with methods for preparing compounds of the present invention and their use.
-
公开(公告)号：US20230096663A1
公开(公告)日：2023-03-30
申请号：US17929006
申请日：2021-02-11
发明人： Robert Judkins , Lambertus Benthem , Rajiv Sharma
摘要： Provided are compounds that can act as a modulator of a farnesoid X receptor (FXR) and that can be useful in the treatment of diseases and/or disorders associated with the FXR. Compositions including such compounds are also provided along with methods for preparing compounds of the present invention and their use.
-
公开(公告)号：US20230135552A1
公开(公告)日：2023-05-04
申请号：US17798702
申请日：2021-02-11
发明人： Lambertus Benthem , Robert Judkins
IPC分类号： C07D417/14 , A61P3/10
摘要： The present invention relates to compounds that can act as inhibitors of ketohexokinase (KHK) and that can be useful in the treatment of diseases and/or disorders associated with KHK. In some embodiments, the present invention relates to compounds and compositions that inhibit KHK and methods for their preparation and use.
-
4.发明授权公开(公告)号：US11339153B2
公开(公告)日：2022-05-24
申请号：US17265266
申请日：2019-08-06
发明人： Rajiv Sharma , Lambertus Benthem , Robert Judkins
IPC分类号： C07D261/08 , C07D451/06 , C07D413/12
摘要： Provided are compounds that can act as a modulator of a farnesoid X receptor (FXR) and that can be useful in the treatment of diseases and/or disorders associated with the FXR such as bile acid related disorders, metabolic syndrome, type-2-diabetes, hyperlipidemia, hypertriglyceridemia, primary biliary cirrhosis (PBC), fatty liver disease, nonalcoholic steatohepatitis (NASH), inflammatory autoimmune diseases, Crohn's disease, multiple sclerosis, atherosclerosis, kidney disorders (including chronic kidney disease), hepatic and colon cancers, and other disorders. The compounds are in the class of sulfinic acid compounds and can be an enantiomer, stereoisomer, tautomer, solvate, hydrate, prodrug, metabolite, or pharmaceutically acceptable salt thereof. Compositions including such compounds are also provided along with methods for preparing compounds of the present invention and their use.
-
-
-
搜索结果
4 条记录 (耗时 0.013 秒)
